Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB22 hours ago · Sanofi expects Dupixent to achieve more than €13 billion in sales in 2024. For Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year.
Sanofi US News
WEB3 days ago · Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB3 days ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB3 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB3 days ago · For Regeneron, which splits U.S. Dupixent revenue with Sanofi, the COPD approval is a needed boost. The company lost nearly $14 billion of its market value earlier this week after a setback in a court case that could allow Amgen to launch a biosimilar version of its eye drug Eylea sooner than investors expected.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEBRegeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage …
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBAbout Sanofi and Regeneron’s COPD Clinical Research Program. Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role …
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBTARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food …
Sanofi US News
WEBMay 20, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBJul 3, 2024 · Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.